EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   1.8.98.2 | Adenocarcinoma |
24189098 |
Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma. |
diagnostic usage
ongoing research
unassigned |
3
4
0 |
| 1.8.98.2 | Adenocarcinoma |
32411320 |
Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
3
2
4 |
| 1.8.98.2 | Brain Injuries |
25407820 |
Sulfiredoxin-1 Attenuates Oxidative Stress via Nrf2/ARE Pathway and 2-Cys Prdxs After Oxygen-Glucose Deprivation in Astrocytes. |
causal interaction
therapeutic application
unassigned |
1
2
0 |
| 1.8.98.2 | Brain Ischemia |
25955519 |
Sulfiredoxin-1 exerts anti-apoptotic and neuroprotective effects against oxidative stress-induced injury in rat cortical astrocytes following exposure to oxygen-glucose deprivation and hydrogen peroxide. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 1.8.98.2 | Brain Ischemia |
28552673 |
Neuroprotective effects of sulfiredoxin-1 during cerebral ischemia/reperfusion oxidative stress injury in rats. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 1.8.98.2 | Breast Neoplasms |
21742584 |
Maesopsin 4-O-beta-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN1 and BCAS3 in acute myeloid leukemia. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
3
3
1
0 |
| 1.8.98.2 | Breast Neoplasms |
22964583 |
Genetic polymorphisms and protein expression of NRF2 and sulfiredoxin predict survival outcomes in breast cancer. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
4
4
1 |
| 1.8.98.2 | Breast Neoplasms |
25833832 |
Correction: Genetic Polymorphisms and Protein Expression of NRF2 and Sulfiredoxin Predict Survival Outcomes in Breast Cancer. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
2
3
1
0 |
| 1.8.98.2 | Carcinogenesis |
21487000 |
Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. |
therapeutic application
unassigned |
1
0 |
| 1.8.98.2 | Carcinogenesis |
23393226 |
Loss of sulfiredoxin renders mice resistant to azoxymethane/dextran sulfate sodium-induced colon carcinogenesis. |
causal interaction
ongoing research
unassigned |
1
3
0 |
